Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arkansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arkansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arkansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Stephan Rosenfeld (NPI 1083685283)

Field	Value
Entity Type	Individual
Organization	Stephan Rosenfeld
Address	3232 N Northhills Blvd
City	Fayetteville
State	AR
ZIP	72703
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 27, 2006

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is the sole payer presence on file: total Medicare revenue is $2.3M while Medicaid billing is listed as none, indicating an effectively single‑payer Medicare revenue base for analyses of utilization and contracting. With the NPI enumerated on 2006-01-27 (~20 years ago) the provider appears to be an established clinician whose billing profile is concentrated in Medicare.

Revenue concentration is high among a small set of oncology-focused codes: the precomputed top 3 Medicare codes by revenue account for 57.2% of total Medicare revenue, driven primarily by J9271 (34.1%), J9299 (14.2%), and 78815 (8.8%). This concentration signals that a majority of Medicare dollars come from high-cost immunotherapy agents and advanced imaging rather than from a broad mix of lower-reimbursement services.

The code mix shows a clear hematology/oncology operating model: J9271 (pembrolizumab) and J9299 (nivolumab) are immune checkpoint inhibitors and together represent nearly half of the top revenue drivers, while 78815 (PET/CT) is a high-revenue imaging study used for tumor staging and treatment planning. Supporting and infusion codes such as 96413 (chemotherapy), 96365/96367 (infusion administration), and specialty agents like J9144 (daratumumab) and J1561 (immune globulin) further reinforce that the practice is delivering systemic oncology therapies and related supportive care.

Competitive standing across top codes is mixed: J9271 ranks #553 of 1841 providers nationally (69th percentile; typical, unremarkable volume for this code), J9299 ranks #292 of 505 (42th percentile; typical, unremarkable volume for this code), and 78815 ranks #1091 of 6566 (83th percentile; typical, unremarkable volume for this code). These ranks suggest the provider is not a national outlier for checkpoint inhibitor administration but shows relatively stronger utilization of PET/CT imaging versus the broader peer set.

One notable utilization outlier is office-based evaluation and management: 99214 appears as an extreme outlier (ranks #6612 of 479517 providers nationally, 99th percentile; extreme outlier, far above typical national volume), indicating a very high volume of moderate-complexity established-patient visits relative to national peers. Adjacent E/M codes such as 99215 and 99204 are at higher percentiles but are characterized as typical or unremarkable, which together point to a practice model with heavy ongoing outpatient management of established oncology patients.

Imaging and diagnostic utilization is elevated relative to peers: besides 78815, CT codes like 74178 rank #182 of 11397 (98th percentile; notably above typical national volume) and 71260 ranks #1403 of 20343 (93th percentile; typical, unremarkable volume for this code). The presence of A9552 (FDG) and high-percentile lab panels (85025 at the 97th percentile, 80053 at the 96th percentile) supports frequent use of staging, monitoring, and laboratory surveillance in the practice’s care pathway.

The provider’s portfolio includes a mix of high-cost biologics and biosimilars and supportive agents—examples include J9144 (daratumumab, 8.0% of Medicare revenue), J1561 (immune globulin, 7.3%), Q5115 (rituximab biosimilar, 3.2%), Q5108 (pegfilgrastim biosimilar, 1.0%), and J0897 (denosumab, 5.6%). Several of these codes rank at typical or below-typical national volumes (for example, J9144 at the 14th percentile), indicating meaningful revenue contribution from specialty therapeutics without consistently high national market share in those specific agents.

From a payer-strategy perspective, the absence of Medicaid billing (none) combined with a Medicare revenue base of $2.3M concentrates risk and negotiation leverage entirely within Medicare lines of business; any network or reimbursement changes in Medicare would disproportionately affect this provider relative to a more diversified payer mix. Contracting and competitive assessments should therefore weight Medicare utilization trends and the provider’s reliance on immunotherapy and imaging services when modeling future revenue scenarios.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

111 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	17,000	$40	$731K
J9299	Injection, nivolumab, 1 mg	12,720	$20	$305.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	190	$1,000	$189.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	4,500	$40	$171K
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	4,120	$40	$156.6K
J0897	Injection, denosumab, 1 mg	6,660	$20	$119.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,230	$80	$103.6K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	1,950	$40	$68.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	600	$90	$52.5K
74178	The provider performs computed tomography of the abdomen and pelvis without contrast material in one or both body regions followed by contrast material in one or both body regions and additional…	170	$180	$30.6K

Showing 1–10 of 111

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 111 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arkansas Distribution

Stephan Rosenfeld — 2 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arkansas

Full comparison — all codes billed, vs. state median

111 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	28	40	20,700	$40	$896.3K
J9299	21	30	15,660	$20	$432.9K
J9144	11	10	10,530	$40	$361.9K
J1561	12	10	5,930	$40	$216.4K
Q5115	18	20	2,800	$30	$95.9K
J0897	38	160	2,580	$20	$89.7K
78815	31	100	90	$550	$83.7K
J0885	32	40	4,070	$10	$38K
96413	24	80	380	$90	$36.6K
A9552	19	40	180	$150	$28.9K

Showing 1–10 of 111

Related Providers

Other providers that share a Tax Identification Number (TIN) with Stephan Rosenfeld, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Shore Hematology Oncology Associates PC	NY	Specialist	$0	$61.9M
Highlands Oncology Group PA	AR	Hematology & Oncology Physician	$0	$5.7M
Matthew Lockwood	AR	Hematology & Oncology Physician	$4.2M	$0
Eric Schaefer	AR	Hematology & Oncology Physician	$3.6M	$0
Patrick Travis	AR	Hematology & Oncology Physician	$3.3M	$0
K'anne Arthur	AR	Hematology & Oncology Physician	$3.2M	$0
Gregory Oakhill	AR	Hematology & Oncology Physician	$2.8M	$0
J Beck	AR	Hematology & Oncology Physician	$2.2M	$0
Dmitriy Zak	AR	Hematology & Oncology Physician	$2.2M	$0
Mitchell Ross	AR	Hematology & Oncology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as Stephan Rosenfeld, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sanders, Tompkins, Schiro, Landers And Sanders PLLC	AR	Pediatric Dentistry	$0	$30.4M
Children's Therapy Services, Inc.	AR	Pediatric Physical Therapist	$0	$29.2M
Life Styles Inc.	AR	Case Management Agency	$0	$19.6M
Washington Regional Medical Center	AR	General Acute Care Hospital	$0	$10.9M
Cross Therapy Services, Ltd	AR	Pediatric Occupational Therapist	$0	$5.8M
Medical Associates Of Northwest Arkansas PA	AR	Pediatrics Physician	$0	$5.8M
Oral & Facial Surgery Center PA	AR	Oral and Maxillofacial Surgery (Dentist)	$0	$4.8M
Thomas A. Sarna, Dds PLLC	AR	Oral and Maxillofacial Surgery Clinic/Center	$0	$3.4M
Washington Regional Medical System	AR	Hospitalist Physician	$0	$3.4M
The Therapy Spot,llc	AR	Speech-Language Pathologist	$0	$3.2M

Stephan Rosenfeld — Billing Profile & Reimbursement Data

Sign up for Stephan Rosenfeld — Billing Profile & Reimbursement Data policy alerts

Stephan Rosenfeld — Billing Profile & Reimbursement Data

Sign up for Stephan Rosenfeld — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References